title: Antibody-based therapeutics--the third generation.
abstract: Peptide Technology Limited (Peptech) recently announced in Australia that its associate company, Cambridge Antibody Technology (CAT) had obtained rights to the commercial development of a new kind of engineered antibody molecule. Diabodies were pioneered by Dr Greg Winter of the Medical Research Council Laboratories in Cambridge. In this article, the origins and potential of diabodies are examined in the context of other recent developments in this very fast moving field.
authors.affiliation: Peptide Technology Limited, N.S.W.
authors.forename: M
authors.initials: M
authors.lastname: Sleigh
mesh_terms: D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000627:therapeutic use*; D000918:Antibody Specificity; D001709:Biotechnology; D006801:Humans; D007135:Immunoglobulin Variable Region
chemical_list: D000911:Antibodies, Monoclonal; D007135:Immunoglobulin Variable Region